Johnson & Johnson (NYSE:JNJ) is one of the most undervalued NYSE stocks to buy now. On July 8, Johnson & Johnson announced ...

Titusville: Johnson & Johnson has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...

Johnson & Johnson (NYSE:JNJ) submitted a supplemental New Drug Application for CAPLYTA®, aiming to prevent schizophrenia ...

Johnson & Johnson (JNJ) said on Tuesday that it has submitted a supplemental new drug application to the U.S. Food and Drug ...

With the addition of CAPLYTA ® to Johnson & Johnson's robust portfolio of therapies, the Company now offers the broadest range of treatment options for adults with schizophrenia. TITUSVILLE, N.J ...

Caplyta may cause problems with body temperature, making it difficult for your body to cool down (heat intolerance).Heavy exercise, extreme heat, dehydration, and certain medicines may worsen heat ...

Patients with stable symptoms of schizophrenia were switched from previous antipsychotic medications with no dose titration to CAPLYTA 42 mg for a 6-week treatment duration, then switched back to ...

CAPLYTA is an oral, once daily medicine approved for the treatment of schizophrenia in adults (42mg/day). The mechanism of action of CAPLYTA in the treatment of schizophrenia is unknown.

Caplyta (lumateperone) is a brand-name oral capsule that’s prescribed for schizophrenia and bipolar depression in adults. If you have problems with side effects from Caplyta, talk with your ...

Intra-Cellular's Caplyta Is Likely A Blockbuster For Bipolar Depression Barring Generic Entry. Mar. 05, 2023 9:14 PM ET Intra-Cellular Therapies, Inc. (ITCI) Stock ITCI 17 Comments 5 Likes.

CAPLYTA is available in 10.5 mg, 21 mg, and 42 mg capsules. Please click here to see full Prescribing Information including Boxed Warnings. About Johnson & Johnson.